First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Stock Information for Lixte Biotechnology Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lixte Biotechnology Holdings Inc.

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.